Abstract
While family planning clinics are hailing the FDA's recent approval of mifepristone (RU-486) as a noninvasive way to terminate an unwanted pregnancy, ob/gyns who decide to administer the drug still need to familiarize themselves with the research on its advantages and disadvantages.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 113-119 |
| Number of pages | 7 |
| Journal | Emergency Medicine |
| Volume | 46 |
| Issue number | 2 |
| State | Published - Feb 2001 |
| Externally published | Yes |
ASJC Scopus subject areas
- Emergency Medicine
- Emergency Medical Services